Common adverse reactions (≥3% incidence over placebo) include voice alteration (12–18%), pharyngitis (32–40%), rash (3–12%), chest pain (18–25%), and rhinitis (27–35%). 

Common and Age-Specific Tolerability Profile

Transient FVC declines ≥10% (single measurements) and dyspnea (serious cases: 12–17%) were noted in advanced disease. Pediatric cohorts (<5 years) reported higher cough (45%) and rhinitis (35%) rates. Allergic manifestations (urticaria, rash) occurred in 2–4% of patients, without anaphylaxis. Antibody development to dornase alfa had no clinical correlation. Mortality rates mirrored CF progression (e.g., respiratory failure, hemoptysis). Long-term carcinogenicity or fertility risks are not specified in the description.